Understand the source comparison
Wolverine Stack vs Single Peptides: Mechanism Comparison
Wolverine Stack Dual ghrelin + GHRH receptor activation Pulsatile (90–120 min duration) GHRP-2/Ipamorelin: 2–3h; CJC-1295: 6–8d 45–65% above baseline Low. Pulses allow receptor recovery Optimal for sustained anabolic signaling and tissue repair applications GH
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Wolverine Stack
- Dual ghrelin + GHRH receptor activation
- Pulsatile (90–120 min duration)
- GHRP-2/Ipamorelin: 2–3h; CJC-1295: 6–8d
- 45–65% above baseline
- Low. Pulses allow receptor recovery
- Optimal for sustained anabolic signaling and tissue repair applications
- GHRP-2 (Monotherapy)
- Ghrelin receptor agonist
- Sharp pulse, rapid clearance (45–60 min)
- 2–3 hours
- 20–30% above baseline
- Moderate. Frequent dosing required
- Effective for acute GH release but lacks duration for downstream IGF-1 synthesis
- CJC-1295 no-DAC (Monotherapy)
- GHRH receptor amplification
- Moderate pulse, extended by endogenous GHRH
- 6–8 days
- 25–35% above baseline
- Low. Weekly dosing sufficient
- Good foundational protocol but limited amplitude without ghrelin co-signal
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic
- Continuous low-amplitude elevation
- 24 hours
- 30–40% above baseline initially, plateaus by week 3
- High. Constant receptor engagement
- Convenient but causes receptor desensitization; anabolic efficiency declines over time
- Ipamorelin (Monotherapy)
- Selective ghrelin receptor agonist
- Moderate pulse, no prolactin/cortisol spike
- 2 hours
- 18–28% above baseline
- Low. Selective binding reduces side effects
- Cleanest safety profile but lower amplitude than GHRP-2; best as part of a stack
- Sermorelin
- GHRH analog (shorter-acting than CJC-1295)
- Moderate pulse, 30–45 min duration
- 10–20 minutes
- 15–25% above baseline
- Low. Mimics natural GHRH
- Too short-acting for once-daily protocols; requires multiple daily injections
- The table demonstrates why Wolverine Stack dominates for research applications requiring sustained GH exposure: no other protocol combines high pulse amplitude, extended duration, and low receptor downregulation risk in a twice-daily administration schedule. MK-677's convenience comes at the cost of receptor desensitization. Single peptides lack the synergistic amplitude boost that dual-pathway activation provides. Sermorelin's ultra-short half-life makes it impractical for most study designs.